In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|August 27, 2026
ACT Brief: AI in Invoice Processing, Botanical Medicines and FDA Pathways, and Connected Trial Finance Systems
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine where agentic AI delivers immediate wins in site payments, how botanical therapies can earn pharmaceutical credibility, and the connected financial systems reshaping trial operations.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part three of his interview , Patrick Mizer, chief technology officer at Ledger Run, describes how agentic AI is being applied to invoice processing, one of the most labor-intensive bottlenecks in site payments. His company built an agentic AI flow that ingests emailed invoices, screens for protected health information, decomposes components, and validates them against systems with accuracy high enough that QC experts cannot distinguish AI outputs from human work in blind testing. - In the
latest Beyond Compliance episode , Joel Stanley, CEO of AJNA BioSciences, discussed why botanical therapies need pharmaceutical-grade standardization and clinical evidence to earn physician trust and insurance coverage. Variability in plant genetics, growing region, and cultivation practices can meaningfully change chemical makeup even when the label stays the same, making consistency the central challenge for botanical medicine development. - In a
new contributed article from IQVIA , authors examined how fragmented financial systems have become constraints limiting visibility, slowing execution, and increasing risk across the trial lifecycle. A connected ecosystem with AI integration shifts clinical trial finance from manual coordination toward automated visibility and real-time decision support, reducing the manual effort that Frost and Sullivan's survey of 300 clinical ops executives identified as the top challenge.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
2
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
3
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
4
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
5